Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Depreciation and Depletion (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Depreciation and Depletion for 11 consecutive years, with $34.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 29.83% to $34.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $131.6 million through Dec 2025, down 21.16% year-over-year, with the annual reading at $131.6 million for FY2025, 21.16% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $34.4 million at BeOne Medicines, down from $35.7 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $70.0 million in Q3 2024, with the low at $9.4 million in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $24.3 million, with a median of $20.1 million recorded in 2023.
  • The sharpest move saw Depreciation and Depletion skyrocketed 263.93% in 2024, then plummeted 48.98% in 2025.
  • Over 5 years, Depreciation and Depletion stood at $12.3 million in 2021, then soared by 38.57% to $17.0 million in 2022, then rose by 22.38% to $20.9 million in 2023, then surged by 135.1% to $49.0 million in 2024, then decreased by 29.83% to $34.4 million in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $34.4 million, $35.7 million, and $29.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.